Search
forLearn
5 / 801 resultslearn ACETYL TETRAPEPTIDE-2
learn AC Retinol Liposome
learn AHK-Cu Copper Tripeptide
learn acetyl methionine
Research
5 / 718 resultsresearch Application and Challenges of Chimeric Antigen Receptor T Cell Therapy in Systemic Rheumatic Diseases and Autoimmune Disorders
CAR-T cell therapy shows promise for treating autoimmune disorders but faces challenges like complex manufacturing and limited tissue penetration.
research 572 Development of immunotherapies targeting TCR-Vβ2 for treatment of cutaneous T cell lymphoma
Targeting TCR-Vβ2 in cutaneous T cell lymphoma shows promise for safer, more specific treatment.
research ZASTOSOWANIE TERAPII CAR-T W ONKOHEMATOLOGII DZIECIĘCEJ
CAR-T therapy offers hope for children with hard-to-treat blood cancers.
research Specific receptor detection by a functional keratinocyte growth factor-immunoglobulin chimera.
A new protein was made to detect specific skin cell growth receptors and worked in normal skin but not in skin cancer cells.
research Androgen Signaling Regulates SARS-CoV-2 Receptor Levels and Is Associated with Severe COVID-19 Symptoms in Men
Male hormones affect COVID-19 severity and certain drugs targeting these hormones could help reduce the risk.
Community Join
5 / 1000+ resultscommunity HMI-115 update: Chime Biologics and Hope Medicine Enter Manufacturing Agreement to Speed up the Launch of First-in-class Antibody Drug HMI-115 Targeting Endometriosis and Androgenic Alopecia
Chime Biologics and Hope Medicine are speeding up the launch of a first-in-class antibody drug, HMI-115, for endometriosis and androgenic alopecia. The treatment involves a series of subcutaneous injections, has shown promising results in phase 1, and continues to promote hair regrowth even after the treatment is stopped.
community Has anyone done research on Absci's AI‑driven antibody platform? Seeking your thoughts!
A user is interested in Absci's AI-driven antibody platform, ABS-201, for treating androgenetic alopecia, which shows promising preclinical results and potential for hair regrowth and pigmentation restoration. However, concerns are raised about the drug's development timeline and its advantages compared to existing treatments.
community Protac degradation of the androgen receptor in mice shows good efficacy and no systemic drug could be found
The efficacy of degrading the androgen receptor through dermal application in DP cells, a delivery system for topical drugs that involves dissolving microneedles, and rosemary oil as an alternative anti-androgen.
community How’s RCH-01 doing?
RCH-01's progress is uncertain, and there's skepticism about its effectiveness. Users are losing hope in this treatment.
community AH-001 another topical AR degrader beside GT20029, completed Phase I
AH-001 is a new topical treatment designed to degrade androgen receptors, targeting the root cause of androgenetic alopecia without the side effects of oral treatments like finasteride. It has shown a strong safety profile and good local tolerability in early trials.